Just saw that AstraZeneca wrapped up a pretty solid bond deal - $2 billion across three separate tranches if you're following along. So they split it into $650M at 4%, another $600M at 4.3%, and $750M at 4.6%, all maturing between 2031 and 2036. Honestly, the rate structure makes sense given where rates are these days. What caught my eye is they're being pretty straightforward about what they're doing with the money - general corporate stuff and potentially refinancing existing debt. Nothing too flashy. The deal closed back in early March, and their stock was trading around 15,218 pence on the London exchange when this was announced. For a pharma company this size, splitting it into three tranches like that is pretty standard risk management. Curious to see how they deploy this capital over the next few years.